论文部分内容阅读
目的观察含肺泰胶囊抗结核治疗方案治疗复治肺结核的临床疗效。方法将113例复治肺结核患者按随机数字表法分为治疗组(58例)和对照组(55例)。两组均采用常规抗结核化疗(治疗方案为3H-R-Z-E/6H-R-E),治疗组加服肺泰胶囊2.5 g,每日3次。两组疗程均为9个月。观察两组患者治疗2、5、8个月末的痰菌阴转率,治疗3、6、9个月末的病灶吸收率及空洞闭合率,治疗1个月末的临床症状缓解率和治疗9个月末不良反应的发生情况。结果治疗2、5、8个月末,治疗组痰菌阴转率分别为[75.00%(21/28)、92.86%(26/28)、96.43%(27/28)]明显高于对照组[41.67%(10/24)、70.83%(17/24)、75.00%(18/24),χ~2=5.96、4.92、5.09,P<0.05]。治疗3、6、9个月末,治疗组病灶吸收总有效率分别为[81.03%(47/58)、94.83%(55/58)、98.28%(57/58)]高于对照组[43.64%(24/55)、61.82%(34/55)、70.91%(39/55),χ~2=16.91、18.39、16.54,P<0.01],且治疗组空洞缩小总有效率分别为[70.00%(28/40)、87.50%(35/40)、95.0%(38/40)]亦优于对照组[27.03%(10/37)、48.65%(18/37)、70.27%(26/37),χ~2=14.20、13.52、8.38,P<0.01]。治疗1个月末,治疗组咳嗽、咳痰、咯血、发热、乏力、盗汗、纳差症状的缓解率均高于对照组(χ~2=4.78、5.59、5.40、4.65、4.25、4.79、4.50,P<0.05)。治疗组药物不良反应发生率为24.13%(14/58),对照组为29.09%(16/55),两组比较,差异无统计学意义(χ~2=0.36,P>0.05)。结论肺泰胶囊与抗结核化疗药物联用治疗复治肺结核,能促进病灶吸收及空洞闭合,加快痰菌转阴。
Objective To observe the curative effect of HanTai capsule antituberculosis treatment on rehabilitative pulmonary tuberculosis. Methods One hundred and thirteen patients with re-treatment of pulmonary tuberculosis were divided into treatment group (58 cases) and control group (55 cases) according to random number table. Conventional anti-TB chemotherapy (3H-R-Z-E / 6H-R-E) was used in both groups. Two groups of treatment are 9 months. At the end of 2, 5, and 8 months of treatment, the sputum negative conversion rate, the lesion absorption rate and the void closure rate at the end of 3, 6, and 9 months of treatment were observed. The clinical symptom relief rate at the end of 1 month and the end of 9 months of treatment Adverse reactions occurred. Results At the end of 2, 5, and 8 months of treatment, the sputum negative conversion rates in the treatment group were significantly higher than those in the control group [75.00% (21/28), 92.86% (26/28), 96.43% (27/28) 41.67% (10/24), 70.83% (17/24), 75.00% (18/24), χ ~ 2 = 5.96,4.92,5.09, P <0.05]. At the end of 3, 6 and 9 months of treatment, the total effective rate of the treatment group was 81.03% (47/58), 94.83% (55/58) and 98.28% (57/58) respectively, higher than that of the control group (43.64% (24/55), 61.82% (34/55), 70.91% (39/55) respectively, χ ~ 2 = 16.91,18.39,16.54, P <0.01]. The total effective rate of cavity shrinkage was 70.00% (28/40), 87.50% (35/40), 95.0% (38/40)] were also better than those in the control group [27.03% (10/37), 48.65% (18/37), 70.27% ), χ ~ 2 = 14.20, 13.52, 8.38, P <0.01]. At the end of one month, the relief rate of cough, expectoration, hemoptysis, fever, fatigue, night sweats and anorexia in the treatment group were higher than those in the control group (χ ~ 2 = 4.78,5.59,5.40,4.65,4.25,4.79,4.50, P <0.05). Adverse drug reaction rate was 24.13% (14/58) in the treatment group and 29.09% (16/55) in the control group. There was no significant difference between the two groups (χ ~ 2 = 0.36, P> 0.05). Conclusions Lung Tai capsule combined with anti-tuberculosis chemotherapy drugs for the treatment of pulmonary tuberculosis, can promote the absorption of the lesion and hollow closure, to speed up the sputum negative.